Channel Therapeutics Corporation
Channel Therapeutics Corporation (CHRO) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · CHRO · as of Jun 9, 2026
Key Statistics
Explore Channel Therapeutics Corporation Data
chro stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 1 · Buy rate: 100.0%
Competitors & Peers
chro competitorsCHRO
APGN
BIOR
CRVO
CSCI
IMVIFStock Performance
Full HistoryAbout Channel Therapeutics Corporation
Channel Therapeutics Corporation operates as a clinical-stage biotechnology company, committed to the entire process of identifying, advancing, and bringing to market novel therapies aimed at reducing…
what is channel therapeutics corporation · chro stock overview · channel therapeutics corporation company profile · who is channel therapeutics corporation ceo · chro AMEX · channel therapeutics corporation headquarters · channel therapeutics corporation business segments
About Stock Overview & Key Data
Channel Therapeutics Corporation (CHRO) is a Healthcare company in the Biotechnology industry, listed on AMEX since Feb 16, 2024. As of the latest trading session, CHRO stock price is $1.35, with a market capitalization of $8.9M. The stock has returned -87.38% over the past 12 months and -81.33% year-to-date.
According to 1 Wall Street analysts, the consensus rating for Channel Therapeutics Corporation stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Channel Therapeutics Corporation reported revenue of $16.8M and net income of -$43.3M. For detailed data — including Channel Therapeutics Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Channel Therapeutics Corporation (CHRO) stock price is $1.35. The stock is traded on AMEX under the ticker symbol CHRO. The 52-week range is $1.23 – $54.29.